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ABSTRACT
OBJECTIVES
To derive and validate updated QDiabetes-2018 
prediction algorithms to estimate the 10 year risk of 
type 2 diabetes in men and women, taking account 
of potential new risk factors, and to compare their 
performance with current approaches.
DESIGN
Prospective open cohort study.
SETTING
Routinely collected data from 1457 general practices 
in England contributing to the QResearch database: 
1094 were used to develop the scores and a separate 
set of 363 were used to validate the scores.
PARTICIPANTS
11.5 million people aged 25-84 and free of diabetes 
at baseline: 8.87 million in the derivation cohort and 
2.63 million in the validation cohort.
METHODS
Cox proportional hazards models were used in the 
derivation cohort to derive separate risk equations 
in men and women for evaluation at 10 years. 
Risk factors considered included those already in 
QDiabetes (age, ethnicity, deprivation, body mass 
index, smoking, family history of diabetes in a first 
degree relative, cardiovascular disease, treated 
hypertension, and regular use of corticosteroids) 
and new risk factors: atypical antipsychotics, statins, 
schizophrenia or bipolar affective disorder, learning 
disability, gestational diabetes, and polycystic ovary 
syndrome. Additional models included fasting blood 
glucose and glycated haemoglobin (HBA1c). Measures 
of calibration and discrimination were determined in 
the validation cohort for men and women separately 
and for individual subgroups by age group, ethnicity, 
and baseline disease status.
MAIN OUTCOME MEASURE
Incident type 2 diabetes recorded on the general 
practice record.
RESULTS
In the derivation cohort, 178 314 incident cases 
of type 2 diabetes were identified during follow-
up arising from 42.72 million person years of 
observation. In the validation cohort, 62 326 incident 
cases of type 2 diabetes were identified from 14.32 
million person years of observation. All new risk 
factors considered met our model inclusion criteria. 
Model A included age, ethnicity, deprivation, body 
mass index, smoking, family history of diabetes in a 
first degree relative, cardiovascular disease, treated 
hypertension, and regular use of corticosteroids, 
and new risk factors: atypical antipsychotics, statins, 
schizophrenia or bipolar affective disorder, learning 
disability, and gestational diabetes and polycystic 
ovary syndrome in women. Model B included the 
same variables as model A plus fasting blood glucose. 
Model C included HBA1c instead of fasting blood 
glucose. All three models had good calibration and 
high levels of explained variation and discrimination. 
In women, model B explained 63.3% of the variation 
in time to diagnosis of type 2 diabetes (R2), the D 
statistic was 2.69 and the Harrell’s C statistic value 
was 0.89. The corresponding values for men were 
58.4%, 2.42, and 0.87. Model B also had the highest 
sensitivity compared with current recommended 
practice in the National Health Service based on 
bands of either fasting blood glucose or HBA1c. 
However, only 16% of patients had complete data for 
blood glucose measurements, smoking, and body 
mass index.
CONCLUSIONS
Three updated QDiabetes risk models to quantify 
the absolute risk of type 2 diabetes were developed 
and validated: model A does not require a blood test 
and can be used to identify patients for fasting blood 
glucose (model B) or HBA1c (model C) testing. Model 
B had the best performance for predicting 10 year 
risk of type 2 diabetes to identify those who need 
interventions and more intensive follow-up, improving 
on current approaches. Additional external validation 
of models B and C in datasets with more completely 
collected data on blood glucose would be valuable 
before the models are used in clinical practice.
1Division of Primary Care, 
University of Nottingham, 
Nottingham NG2 7RD, UK
2ClinRisk, Leeds, West Yorkshire, 
UK
Correspondence to:  
J Hippisley-Cox  
Julia.hippisley-cox@nottingham.
ac.uk
Additional material is published 
online only. To view please visit 
the journal online.
Cite this as: BMJ 2017;359:j5019 
http://dx.doi.org/10.1136/bmj.j5019
Accepted: 16 October 2017
WhAT iS AlReAdy knoWn on ThiS TopiC
Methods to identify those at increased risk of type 2 diabetes are needed to identify 
patients for whom interventions or more frequent assessment may be required
QDiabetes is currently widely used to estimate 10 year risk of type 2 diabetes in 
people aged 25-84 years both to communicate risk to patients and to identify 
patients at high risk for interventions and active surveillance
QDiabetes does not include some well established risk factors and so will 
underestimate risk in these patients
It also does not include fasting blood glucose or HBA1c values
WhAT ThiS STudy AddS
Updated algorithms (QDiabetes-2018) were developed to quantify absolute risks 
of type 2 diabetes in adults aged 25-84, which include established risk factors 
and new risk factors such as atypical antipsychotics, statins, schizophrenia 
or bipolar affective disorder, learning disability, gestational diabetes, and 
polycystic ovary syndrome, and also can incorporate fasting blood glucose and 
HBA1c values
The updated risk algorithms provide valid measures of absolute risk in the 
general population of patients as shown by the performance in a separate 
validation cohort
The model that includes fasting blood glucose had the best discrimination and 
the highest sensitivity compared with current recommended practice in the NHS 
based on bands of either fasting blood glucose or HBA1c
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introduction
Diabetes risk assessment tools are used to identify 
people at increased risk of diabetes so they can have 
blood tests, and to target interventions to reduce risk. The 
first QDiabetes model to estimate 10 year risk of type 2 
diabetes was published in 2009.1 Since then it has been 
updated regularly and recalibrated to the latest version 
of the QResearch database; the age range across which 
it applies has also been extended, from 25-79 to 25-84 
years, smoking is assessed at five levels instead of two, 
and the Townsend score has been updated using most 
recent values from the 2011 census.2-4 This helps ensure 
that the algorithm reflects the changes in population 
characteristics (such as changes in prevalence of 
smoking, body mass index, and incidence of type 2 
diabetes) and improvements in data quality such as 
improved recording of risk factors or ascertainment 
of diabetes. The QDiabetes algorithms have been 
validated by ourselves and others in independent 
groups of patients using UK primary care databases 
such as QResearch,5 Clinical Practice Research Datalink 
(CPRD),5 and The Health Improvement Network (THIN).6 
The algorithms have been independently and externally 
validated in international populations and compared 
with other diabetes risk prediction models and been 
shown to have best performance.7 The use of QDiabetes 
has also been evaluated in observational studies and 
systematic reviews.8-11
QDiabetes is now integrated into leading UK general 
practice computer systems and used within the UK 
National Health Service. It is recommended in the NHS 
Health Checks and National Institute for Health and 
Care Excellence guidance on the prevention of type 
2 diabetes in people at high risk.12 13 It is also used 
in occupational health settings and internationally 
through the publicly available QDiabetes website (www.
qdiabetes.org). A recent update to the NICE guideline 
on diabetes prevention in 2017 has highlighted 
several conditions associated with increased diabetes 
risk that may not be fully captured by QDiabetes.14 
These include polycystic ovary syndrome, gestational 
diabetes, learning disabilities, and mental health 
problems.15 Furthermore, there is now good evidence 
from both clinical trials and observational studies 
that atypical antipsychotics and statins are associated 
with an increased risk of diabetes.16-23 These factors 
are not specifically identified within QDiabetes, which 
may result in under-estimation of risk in the relevant 
patient groups.
Once patients with an increased risk of developing 
diabetes have been identified using a diabetes risk 
assessment tool such as QDiabetes, then guidelines 
recommend they undergo a blood glucose test, either 
for glycated haemoglobin (HBA1c) or fasting blood 
glucose.12 13 24 This is to determine who already has 
diabetes; who is at high risk of progression to type 2 
diabetes, and who is at moderate risk.13 International 
guidelines differ about which thresholds of fasting 
blood glucose and HBA1c to use to define the high risk 
group, mainly because of a lack of population based 
data on which to base the analyses.25 26 For example, 
American guidelines recommend a fasting blood 
glucose concentration of 5.6-6.9 mmol/L or HBA1c 
value of 39-46 mmol/mol (5.7-6.4%). UK guidelines 
recommend a fasting blood glucose concentration of 
5.5-6.9 mmol/L or HBA1c value of 42-47 mmol/mol 
(6.0-6.4%).12
Widely used risk assessment tools do not incorporate 
the results of either blood test, making it difficult to 
provide patients with an accurate estimation of their 
absolute level of risk after a blood test. We therefore 
derived and validated a new version of the equation 
(QDiabetes-2018) to determine whether these factors 
should be incorporated into the equation and how they 
could be used to improve the estimation of diabetes 
risk and communication with patients as well as 
improve the design of population based diabetes risk 
assessment strategies.
Methods
Study design and data source
We undertook a cohort study in a large population of 
primary care patients in England who were registered 
with practices contributing to the QResearch database 
(version 42). EMIS Health is the leading commercial 
supplier of general practice computer systems in the 
UK and is used by approximately 4400 practices. 
This is around 58% of all 7613 general practices in 
England (NHS Information Centre, March 2016). Of 
these, 1503 (34.2%) contribute to the QResearch 
database. We included all English practices 
contributing to QResearch who had been using their 
EMIS Health computer system for at least a year. We 
randomly allocated three quarters of practices to the 
derivation dataset and the remaining quarter to a 
validation dataset. We identified an open cohort of 
patients aged 25-84 years registered with practices 
between 1 January 2005 and 31 December 2016. We 
excluded patients who did not have a postcode related 
Townsend score (these usually result from patients 
moving to newly built houses with new postcodes 
not yet linked to deprivation data, or from patients 
being homeless or not having a permanent residence) 
and those with pre-existing type 1 or type 2 diabetes. 
We also excluded those with a fasting blood glucose 
concentration of 7 mmol/L or more or HBA1c value of 
48 mmol/mol or more as these patients might be in the 
process of having further tests to confirm a diagnosis of 
diabetes. For each patient we determined an entry date 
to the cohort, which was the latest of the following: 
25th birthday, date of registration with the practice 
plus one year, date on which the practice computer 
system was installed plus one year, and the beginning 
of the study period (1 January 2005). Patients were 
censored at the earliest date of the diagnosis of type 2 
diabetes, death, deregistration with the practice, last 
upload of computerised data, or the study end date (31 
December 2016).
Outcomes
Our primary outcome measure was the first (incident) 
diagnosis of type 2 diabetes mellitus as recorded on 
RESEARCH
the bmj | BMJ 2017;359:j5019 | doi: 10.1136/bmj.j5019 3
the general practice computer records. We identified 
patients with diabetes by searching the electronic 
health record for diagnostic Read codes for diabetes 
(C10%). As in other studies, we classified patients 
as having type 2 diabetes if they had a diagnosis of 
diabetes and had not been prescribed insulin aged less 
than 35 years.1 27 28
Predictor variables
We examined the following predictor variables based 
on established risk factors already included in the 
current version of QDiabetes-2017 and new candidate 
variables highlighted in the literature or NICE 
guidelines. Where diagnoses are mentioned, these 
relate to diagnostic codes recorded in the patients’ 
electronic health record on or before the study entry 
date.
Existing variables from QDiabetes (current 2017 
version)
•   Age at study entry (baseline)
•   Ethnicity (nine categories)
•   Deprivation  (as measured  by  the  Townsend  score, 
where higher values indicate higher levels of 
material deprivation)
•   Body mass index
•   Smoking  status:  non-smoker,  former  smoker,  light 
smoker (1-9/day), moderate smoker (10-19/day), 
heavy smoker (≥20/day)
•   Family history of diabetes in a first degree relative
•   Cardiovascular  disease  (ischaemic  heart  disease, 
stroke, or transient ischaemic attack)
•   Treated hypertension (diagnosis of hypertension and 
current treatment with at least one antihypertensive 
drug)
•   Corticosteroids  (British National Formulary 
chapter 6.3.2, including oral or injections of 
systemic prednisolone, betamethasone, cortisone, 
depo-medrone, dexamethasone, deflazacort, 
efcortesol, hydrocortisone, methylprednisolone, or 
triamcinolone)
New or amended risk factors considered
•   Diagnosis  of  schizophrenia  or  bipolar  affective 
disorder
•  Learning disabilities
•  Diagnosis of gestational diabetes
•  Diagnosis of polycystic ovary syndrome
•   Prescribed  second  generation  “atypical” 
antipsychotics (including amisulpride, aripiprazole, 
clozapine, lurasidone, olanzapine, paliperidone, 
quetiapine, risperidone, sertindole, and zotepine)
•  Prescribed statins
•  Fasting blood glucose level
•  Glycated haemoglobin (HBA1c) value
From the general practice record we extracted data 
on the demographic factors, clinical diagnoses, and 
clinical values. We selected the closest value to cohort 
entry for body mass index, smoking status, fasting 
blood glucose level, and HBA1c level, restricting to 
values recorded before baseline. Use of drugs at baseline 
was defined as at least two prescriptions in total, with 
the most recent one no more than 28 days before the 
date of entry to the cohort. All other predictor variables 
were based on the latest information recorded in the 
general practice record before entry to the cohort.
Derivation and validation of the models
We developed and validated the risk prediction 
equations using established methods.10 29-32 An 
initial analysis was performed based on patients 
with complete data. We used multiple imputation 
with chained equations to replace missing values 
for body mass index, HBA1c, fasting blood glucose, 
and smoking status and used these values in our 
main analyses.33-35 So that the imputed values would 
better match the distribution of observed values, 
we log transformed values for continuous variables 
that were not normally distributed for inclusion in 
the imputation model. In that model we included 
all predictor variables, along with the Nelson-Aalen 
estimator of the baseline cumulative hazard, and the 
outcome indicator. We carried out five imputations, 
as this has a relatively high efficiency36 and was a 
pragmatic approach accounting for the size of the 
datasets and capacity of the available servers and 
software. The same imputed dataset was used for all 
the derivation analyses.
To estimate the coefficients for each risk factor 
in men and women separately we used Cox’s 
proportional hazards models. We used Rubin’s rules 
to combine the results across the imputed datasets.37 
We used fractional polynomials38 to model non-linear 
risk relations with continuous variables. We selected 
second degree fractional polynomial terms derived 
using the data from patients with recorded values.39 
Before running the Cox models we applied the fractional 
polynomial terms to the imputed data. Initially we fitted 
full models. For consistency, we included variables 
from existing QDiabetes models and then retained 
additional variables if they had an adjusted hazard 
ratio of less than 0.90 or more than 1.10 (for binary 
variables) and were statistically significant at the 
0.01 level. We used these criteria in conjunction with 
clinical judgment to ensure that candidate variables 
were likely to be clinically important and to reduce 
the possibility of including weak or uninformative 
predictors that could lead to model over-fitting and 
optimism.40 We examined interactions between new 
predictor variables and age at study entry and included 
significant interactions in the final models along with 
interactions already included in the current version of 
QDiabetes. To compare fit and performance of different 
models in the derivation cohort we used Akaikes 
Information Criterion.
We developed three main models. Model A included 
the variables in the existing QDiabetes models and the 
additional variables that met our inclusion criteria but 
did not include either fasting blood glucose or HBA1c. 
Model B is the same as model A except that it included 
fasting blood glucose but not HBA1c. Model C is the 
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same as model A except that it included HBA1c but not 
fasting blood glucose.
We used the regression coefficients for each variable 
from the final models as weights, which we combined 
with non-parametric estimates of the baseline survivor 
function,41 evaluated for each year up to 10 years to 
derive risk equations over 10 years of follow-up.42 
This enabled us to derive risk estimates for each year 
of follow-up, with a specific focus on 10 year risk 
estimates. We estimated the baseline survivor function 
based on zero values of centred continuous variables, 
with all binary predictor values set to zero.
Validation of the models
In the validation cohort we used multiple imputation 
to replace missing values for body mass index, 
fasting blood glucose, HBA1c, and smoking status. 
We carried out five imputations. The risk equations 
for men and women obtained from the derivation 
cohort were then applied to the validation cohort and 
measures of discrimination calculated. As in previous 
studies,5 we calculated the D statistic43 (a measure of 
discrimination where higher values indicate better 
discrimination), R2 value (explained variation where 
higher values indicate a greater proportion of variation 
explained by the model in time to diagnosis of type 2 
diabetes44) based on Royston’s D statistic, and Harrell’s 
C statistic at 10 years and combined these across 
datasets using Rubin’s rules. Harrell’s C statistic45 
is a measure of discrimination similar to the receiver 
operating characteristic statistic but takes account of 
the censored nature of the data.
Calibration was assessed by comparing the mean 
predicted risks at 10 years with the observed risk 
by 10th of predicted risk. The observed risks were 
obtained using the Kaplan-Meier estimates evaluated 
at 10 years. We also evaluated performance by 
subgroups for each age band (<40, 40-59, ≥60 years), 
ethnic minority group, and comorbidity and treatment 
group. We calculated calibration slopes. Performance 
was also evaluated by calculating Harrell’s C statistics 
in individual general practices and combining the 
results using meta-analytical techniques.46
By applying each equation to the validation dataset 
we compared performance statistics for the new 
QDiabetes-2018 models with the latest version of 
QDiabetes (2017 version).
Risk stratification
For model A we calculated sensitivity, specificity, 
and observed risks at different risk thresholds in the 
validation cohort.
We also compared performance of the models with 
current recommendations from the “two step” approach 
recommended in the NICE guidance “Preventing type 
2  diabetes  risk”13 and the NHS Health Checks best 
practice guideline.12 Step 1 currently involves using a 
risk assessment tool such as QDiabetes to identify “high 
risk” patients, where high risk is defined for QDiabetes 
as those who have a 10 year risk of type 2 diabetes of 
5.6% or greater.12 This threshold appears to have been 
selected predominantly to optimise sensitivity (ie, to 
avoid missing cases of type 2 diabetes). Step 2 involves 
a blood test for those identified at high risk to assess 
whether they have undiagnosed type 2 diabetes, and 
in the remaining patients to more accurately stratify 
their risk of progression to diabetes. This blood test 
can be either for fasting blood glucose or for HBA1c in 
high risk patients to classify patients into one of three 
groups: fasting blood glucose ≥7 mmol/L or HBA1c 
≥48  mmol/mol = diagnosis of diabetes (or further 
testing required for confirmation if patient has no 
symptoms); fasting blood glucose 5.5-6.9 mmol/L or 
HBA1c 42-47 mmol/mol = “high risk of diabetes” for 
intensive lifestyle advice or intervention programme; 
and fasting blood glucose <5.5 mmol/L or HBA1c <42 
mmol/mol  =  “moderate  risk  of  diabetes”  for  simple 
lifestyle advice.
The updated QDiabetes models were designed to 
support such an approach, with model A intended 
to identify patients with an increased risk for whom 
a blood test could be done. The two further models 
(model B including fasting blood glucose and model 
C including HBA1c) could then be used to refine the 
risk assessment tool once the relevant blood test result 
was available. Risk assessment at this point could also 
allow communication of a more accurate risk estimate 
for patients to inform their decision making and 
management plans.
To compare performance of the models with current 
recommendations, we calculated the sensitivity for 
four different strategies for classifying patients as high 
risk of progression for diabetes using the validation 
cohort. Patients were classified as at high risk if they 
had an initial 10 year QDiabetes risk score of 5.6% or 
more (using model A) and (i) they had a fasting blood 
glucose concentration between 5.5 and 6.9 mmol/L 
(strategy 1), (ii) an HBA1c value between 42 and 47 
mmol/mol (strategy 2), (iii) a risk score in the top 28% 
of risk scores using model B (which includes fasting 
blood glucose values) to correspond to the number of 
high risk patients for strategy 1 (strategy 3), and (iv) 
a risk score in the top 28% of risk scores using model 
C (which includes HBA1c values) to correspond to the 
number of high risk patients for strategies 1 and 3 
(strategy 4).
Decision curve analysis
To evaluate the net benefits of the updated risk 
equations we used decision curve analysis in the 
validation cohort.47-49 This approach assesses the 
benefits of correctly detecting people who will develop 
type 2 diabetes compared with the harms from a false 
positive classification (which could lead to unnecessary 
intervention). The net benefit of a risk equation at 
a given risk threshold is given by calculating the 
difference between the proportion of true positives and 
the proportion of false positives multiplied by the odds 
defined by the risk threshold value.48 We calculated 
the net benefits of models A, B, and C across a range 
of threshold probabilities and compared these with 
alternative strategies, such as assuming no patients 
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will develop type 2 diabetes (no intervention) or 
assuming all patients will develop type 2 diabetes 
(intervention in all patients). In general, the strategy 
with the highest net benefit at any given risk threshold 
is considered to have the most clinical value.
To maximise the power and generalisability of 
the results, we used all the relevant patients on the 
database. Stata (version 14) was used for all analyses. 
We adhered to the TRIPOD statement for reporting.40
Patient involvement
Since the original publication of QDiabetes-2009 
there has been public stakeholder discussion about 
methods for assessment of diabetes risk as part of the 
development of the NICE guidance and NHS Health 
Checks.50 We therefore decided to focus on issues 
already identified in NICE guidance and the literature. 
We decided it would be more effective to discuss 
the addition of new variables once the paper was 
published and the relative importance of individual 
risk factors has been quantified. Given the widespread 
implementation of QDiabetes within the NHS and its 
inclusion in guidelines, this would allow for feedback 
from stakeholders (including patient groups and 
charities) as to which changes would be most beneficial 
and how improvements might be implemented.
Results
Study population
Overall, 1457 QResearch practices in England met our 
inclusion criteria (96.9% of all practices contributing 
to QResearch). Of these, three quarters (n=1094) 
were randomly assigned to the derivation dataset, 
with the remaining quarter (n=363) assigned to a 
validation cohort. We identified 8 640 363 patients 
in the derivation cohort aged 25-84 years of whom 
we sequentially excluded 26 602 (0.3%) who did not 
have a recorded Townsend score, 34 195 (0.4%) who 
had a diagnosis of type 1 diabetes at baseline, 342 858 
(4.0%) who had a diagnosis of type 2 diabetes at 
baseline, 23 522 (0.3%) with a fasting blood glucose 
concentration of 7 mmol/L or more at baseline, and 
26 481 (0.3%) with a HBA1c value of 48 mmol/mol or 
more at baseline. This left 8 186 705 for the derivation 
analysis.
We identified 2 779 075 patients in the validation 
cohort aged 25-84 years of whom we sequentially 
excluded 7971 (0.3%) who did not have a recorded 
Townsend score, 11 076 (0.4%) who had a diagnosis 
of type 1 diabetes at baseline, 113 653 (4.1%) who had 
a diagnosis of type 2 diabetes at baseline, 7758 (0.3%) 
with a fasting blood glucose of 7 mmol/L or more, and 
8677 (0.3%) with a HBA1c concentration of 48 mmol/
mol or more at baseline. This left 2 629 940 for the 
validation analysis.
Baseline characteristics
Table 1 shows the baseline characteristics of men 
and women in the derivation and validation cohorts. 
In the derivation cohort, the mean age was 44.9 (SD 
15.3) years, and 4 062 142 (49.6%) were men. Self 
assigned ethnicity was recorded in 5 933 548 (72.5%), 
smoking status in 7 834 644 (95.7%), body mass 
index in 6 482 691 (79.2%), fasting blood glucose in 
1 189 398 (14.5%), and HBA1c in 506 776 (6.2%). In 
total, 6 453 196 (78.8%) had complete information for 
smoking status and body mass index, and 1 367 483 
(16.7%) had complete information for smoking, body 
mass index, and either fasting blood glucose or HBA1c. 
These values were similar to corresponding values in 
the validation cohort (table 1).
Table 1 also shows medical characteristics at study 
entry. For the new variables of interest: 58 655 (0.7%) 
patients in the derivation cohort were prescribed 
atypical antipsychotics, 526 969 (6.4%) were 
prescribed statins, schizophrenia or bipolar affective 
disorder was recorded in 62 014 (0.8%), learning 
disability was recorded in 56 092 (0.7%), gestational 
diabetes in 17 214 (0.4% of women), and polycystic 
ovary syndrome in 81 164 (2.0% of women).
Supplementary table 1a shows the distribution of 
risk factors by ethnic group in the derivation cohort. 
Testing for fasting blood glucose and HBA1c was 
higher among all non-white ethnic groups other than 
Chinese compared with the white or not recorded 
group. Compared with the other ethnic groups, people 
of South Asian and Caribbean origin tended to have 
marginally higher mean HBA1c values, and higher 
proportions had a family history of diabetes.
Supplementary table 1b shows similar information 
for patients with fasting blood glucose or HBA1c 
recorded compared with those without a value for 
either test.
Incidence of type 2 diabetes
Table 2 shows the numbers of patients with a new 
diagnosis of type 2 diabetes during follow-up in the 
derivation and validation cohorts. In the derivation 
cohort, we identified 178 314 incident cases of type 
2 diabetes arising from 42.7 million person years 
of observation. Supplementary table 2 shows a 
breakdown by nine ethnic groups. For example, 6181 
incident cases of type 2 diabetes for men and women 
of Indian ethnicity arose from 795 000 person years of 
observation.
The median follow-up in the derivation cohort was 
3.90 years (interquartile range 1.54 to 8.50). Overall, 
2 027 279 patients had 10 or more years of follow-up. 
The median follow-up in the validation cohort was 
4.22 years (1.57 to 9.25). Overall, 602 661 patients 
had 10 or more years of follow-up.
Predictor variables
Table 3 shows the adjusted hazard ratios for models A, 
B, and C in women in the derivation cohort. Table 4 
shows the corresponding values for men.
Of the new risk factors, all met our model inclusion 
criteria. Model A includes the variables: age, 
ethnicity, deprivation, body mass index, smoking 
status, family history of diabetes in a first degree 
relative, cardiovascular disease, treated hypertension, 
corticosteroids, atypical antipsychotics, statins, 
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schizophrenia or bipolar affective disorder, and 
learning disability. The model in women also included 
gestational diabetes and polycystic ovary syndrome.
Model B is the same as model A except it includes 
fasting blood glucose. Model C is the same as model A 
except it includes HBA1c.
Supplementary figure S1 shows graphs of the 
adjusted hazard ratios for models A and B for the 
fractional polynomial terms for age and body mass 
index as well as the interaction terms between age and 
relevant predictor variables as listed in the footnotes 
of tables 3 and 4. Supplementary figure S1 also shows 
graphs of the adjusted hazard ratios for fasting blood 
glucose in model B and HBA1c in model C and their 
interactions with age.
For the new variables of interest in model A, atypical 
antipsychotics were associated with a 74% (95% 
confidence interval 60% to 89%) increased risk of type 
2 diabetes in women and a 52% (40% to 65%) increased 
risk for men; statins were associated with a 93% (84% 
to 103%) increased risk in women and a 79% (74% to 
86%) increased risk in men; schizophrenia or bipolar 
affective disorder was associated with a 30% (21% 
to 39%) increased risk in women and a 26% (18% to 
34%) increased risk in men; learning disability was 
associated with a 32% (19% to 46%) increased risk 
in women and a 26% (16% to 38%) increased risk 
in  men.  Gestational  diabetes  was  associated  with  a 
359% (332% to 388%) increased risk in women and 
polycystic ovary syndrome was associated with a 41% 
(33% to 49%) increased risk. Where there were age 
interactions, these values relate to risks evaluated at 
the mean ages.
The footnotes for tables 3 and 4 contain the full 
list of age interactions for each model. In both men 
and women, among the new variables there were 
Table 1 | Baseline characteristics of adults aged 25-84 without diabetes at study entry. Values are numbers 
(percentages) of patients unless stated otherwise
Characteristics Derivation cohort (n=8 186 705) Validation cohort (n=2 629 940)
Men 4 062 142 (49.6) 1 307 505 (49.7)
Women 4 124 563 (50.4) 1 322 435 (50.3)
Mean (SD) age (years) 44.9 (15.3) 45.6 (15.5)
Mean (SD) Townsend score 0.5 (3.3) 0.2 (3.2)
Body mass index recorded 6 482 691 (79.2) 2 03 3369 (77.3)
 Mean (SD) body mass index 26.0 (5.0) 26.0 (5.0)
Fasting blood glucose recorded 1 189 398 (14.5) 373 808 (14.2)
 Mean (SD) fasting blood glucose (mmol/L) 5.0 (0.6) 5.0 (0.6)
HBA1c recorded 506 776 (6.2) 161 966 (6.2)
 Mean (SD) HBA1c (mmol/mol) 37.2 (4.5) 37.3 (4.4)
Complete data* 6 453 196 (78.8) 2 024 909 (77.0)
Complete data† 1 367 483 (16.7) 416 142 (15.8)
Ethnic origin:
 Ethnicity recorded 5 933 548 (72.5) 1 870 332 (71.1)
 White or not recorded 7 136 377 (87.2) 2 323 760 (88.4)
 Indian 188 049 (2.3) 58 084 (2.2)
 Pakistani 101 231 (1.2) 33 954 (1.3)
 Bangladeshi 81 834 (1.0) 22 148 (0.8)
 Other Asian 122 981 (1.5) 38 222 (1.5)
 Caribbean 80 657 (1.0) 22 379 (0.9)
 Black African 179 423 (2.2) 48 446 (1.8)
 Chinese 65 999 (0.8) 15 947 (0.6)
 Other 230 154 (2.8) 67 000 (2.5)
Smoking status:
 Smoking recorded 7 834 644 (95.7) 2 520 127 (95.8)
 Non-smoker 4 441 795 (54.3) 1 422 825 (54.1)
 Former smoker 1 518 799 (18.6) 502 297 (19.1)
 Light smoker 1 098 645 (13.4) 344 874 (13.1)
 Moderate smoker 485 756 (5.9) 155 933 (5.9)
 Heavy smoker 289 649 (3.5) 94 198 (3.6)
Medical characteristics:
 Family history of diabetes 1 21 8682 (14.9) 379 889 (14.4)
 Treated hypertension 737 303 (9.0) 249 614 (9.5)
 Cardiovascular disease 290 345 (3.5) 101 370 (3.9)
 Schizophrenia or bipolar affective disorder 62 014 (0.8) 19 619 (0.7)
 Learning disability 56 092 (0.7) 18 458 (0.7)
 Gestational diabetes‡ 17 214 (0.4) 5201 (0.2)
 Polycystic ovary syndrome‡ 81 164 (2.0) 24 217 (0.9)
Current drugs:
 Statins 526 969 (6.4) 173 528 (6.6)
 Atypical antipsychotics 58 655 (0.7) 19 776 (0.8)
 Corticosteroids 238 683 (2.9) 83 760 (3.2)
*Complete data for body mass index and smoking.
†Complete data for body mass index, smoking, and either HBA1c or fasting glucose.
‡% of all women.
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statistically significant interactions between age and 
learning disability, age and atypical antipsychotics, age 
and statins, and age and fasting blood glucose (model 
B), and between age and HBA1c (model C). Hazard 
ratios for learning disability, atypical antipsychotics 
and statins, body mass index, and family history of 
diabetes were higher at younger ages compared with 
older ages (supplementary figure S1c-g). For example, 
for model B in men, statins were associated with a 
141% increased risk at age 35, a 66% increased risk 
at age 45, a 30% increased risk at age 55, and a 15% 
increased risk at age 65 (supplementary figure S1d).
Overall the hazard ratios for models B and C tended 
to be lower than those for model A. The hazard ratios 
for non-white ethnic groups tended to be lower for 
model C than for model B. For example, the hazard 
ratio for Bangladeshi women was 6.07 (5.77 to 6.38) 
for model A, 4.45 (4.20 to 4.73) for model B, and 3.30 
(3.10 to 3.52) for model C.
Supplementary tables 3 and 4 show the results of the 
complete case analysis for each of the three models. 
The adjusted hazard ratios for models A and B are 
broadly similar to the analysis based on imputed data.
Validation
Discrimination
Table 5 shows the performance of each equation in 
the validation cohort for women and men for each 
of models A, B, and C compared with the current 
QDiabetes model. All models had good calibration and 
high levels of explained variation and discrimination. 
Model B had the best overall performance, followed 
by model C. Model A has a similar performance to the 
current QDiabetes models. Performance of all models 
was marginally better among women than among men.
In women, model A explained 50.5% of the 
variation in time to diagnosis of type 2 diabetes (R2), 
the D statistic was 2.07, and the Harrell’s C statistic 
was 0.834. The corresponding values for model A in 
men were 46.6%, 1.91, and 0.814.
In women, model B explained 63.3% of the variation 
in time to diagnosis of type 2 diabetes (R2), the D 
statistic was 2.69, and the Harrell’s C statistic was 
0.889. The corresponding values for model B in men 
were 58.4%, 2.42, and 0.866.
In women, model C explained 60.3% of the variation 
in time to diagnosis of type 2 diabetes (R2), the D 
statistic was 2.52, and the Harrell’s C statistic was 
0.878. The corresponding values for model C in men 
were 55.5%, 2.28, and 0.855.
In addition, we calculated Harrell’s C statistics for 
model B on the subgroup of patients with complete 
data for fasting blood glucose and for model C on 
those with complete data for HBA1c. The results for 
model B were 0.836 for women and 0.812 for men. 
The corresponding results for model C were 0.772 and 
0.738.
Supplementary table 5 shows the D, R2, and Harrell’s 
C statistics for models A and B for women in various 
subgroups, including three age groups, ethnic groups, 
and those with specific morbidities. Supplementary 
table 6 shows the corresponding values for men.
Table 2 | Incidence of type 2 diabetes per 1000 person years with 95% confidence intervals in derivation and validation cohorts
Variables
Derivation cohort Validation cohort
Incident 
cases
Person  
years (000s)
Incidence per  
1000 (95% CI)
Incident 
cases
Person  
years (000s)
Incidence per  
1000 (95% CI)
Total 178 314 42 718 4.17 (4.15 to 4.19) 62 326 14 317 4.35 (4.32 to 4.39)
Women 77 895 21 561 3.61 (3.59 to 3.64) 27 311 7242 3.77 (3.73 to 3.82)
Men 100 419 21 157 4.75 (4.72 to 4.78) 35 015 7076 4.95 (4.90 to 5.00)
Age band (years):
 25-29 2351 5042 0.47 (0.45 to 0.49) 809 1593 0.51 (0.47 to 0.54)
 30-34 6058 5442 1.11 (1.09 to 1.14) 2000 1699 1.18 (1.13 to 1.23)
 35-39 11 419 5580 2.05 (2.01 to 2.08) 3952 1807 2.19 (2.12 to 2.26)
 40-44 16 770 5336 3.14 (3.10 to 3.19) 5519 1778 3.10 (3.02 to 3.19)
 45-49 20 199 4502 4.49 (4.42 to 4.55) 6863 1509 4.55 (4.44 to 4.66)
 50-54 21 698 3776 5.75 (5.67 to 5.82) 7203 1289 5.59 (5.46 to 5.72)
 55-59 24 688 3668 6.73 (6.65 to 6.82) 8862 1305 6.79 (6.65 to 6.93)
 60-64 22 518 2906 7.75 (7.65 to 7.85) 8021 1031 7.78 (7.61 to 7.95)
 65-69 20 039 2315 8.66 (8.54 to 8.78) 7256 827 8.78 (8.58 to 8.98)
 70-74 16 102 1829 8.81 (8.67 to 8.94) 5844 655 8.92 (8.69 to 9.15)
 75-79 10 818 1399 7.73 (7.59 to 7.88) 3892 493 7.89 (7.65 to 8.14)
 80-84 5654 923 6.13 (5.97 to 6.29) 2105 333 6.33 (6.07 to 6.61)
Medical characteristics:
 Family history of diabetes 44 822 6360 7.05 (6.98 to 7.11) 15 951 2104 7.58 (7.46 to 7.70)
 Treated hypertension 54 367 4491 12.11 (12.00 to 12.21) 19 202 1574 12.20 (12.03 to 12.38)
 Cardiovascular disease 20 206 1583 12.76 (12.59 to 12.94) 7310 570 12.82 (12.53 to 13.11)
 Schizophrenia or bipolar  affective disorder 2506 272 9.21 (8.86 to 9.58) 856 89 9.61 (8.99 to 10.28)
 Learning disability 1313 251 5.22 (4.95 to 5.51) 426 84 5.05 (4.59 to 5.56)
 Gestational diabetes 1123 63 17.75 (16.74 to 18.82) 345 19 17.72 (15.95 to 19.69)
 Polycystic ovary syndrome 1243 322 3.85 (3.65 to 4.08) 428 99 4.34 (3.94 to 4.77)
Current drugs:
 Statins 37 231 2,879 12.93 (12.80 to 13.06) 12 603 977 12.89 (12.67 to 13.12)
 Atypical antipsychotics 2350 247 9.50 (9.12 to 9.89) 832 84 9.86 (9.22 to 10.56)
 Corticosteroids 13 390 1579 8.48 (8.34 to 8.63) 4849 574 8.45 (8.21 to 8.69)
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The best performance by ethnic group was for 
model B among Chinese women (R2=68.0%, D=2.99, 
Harrell’s C=0.912). The poorest performance by ethnic 
group was for model A among Bangladeshi women 
(R2=35.6%, D=1.52, Harrell’s C=0.776). Performance 
values were highest in the youngest age group (<40 
years) and lowest in the oldest age group (≥60 years) 
for both models.
Supplementary figure S2a-d shows plots of Harrell’s 
C statistic for models A and B in men and women 
across the 363 practices in the validation cohort. The 
plots show Harrell’s C values for each general practice 
versus the number of patients with a diagnosis of type 2 
diabetes in each practice. Practices with fewer patients 
with a diagnosis of type 2 diabetes had wider variation 
in C statistic than practices with more diagnoses. 
For example, supplementary figure 2a shows the 
summary (average) C statistic for model A in women 
was 0.834 from a random effects meta-analysis. The 
I2 value (ie, the percentage of total variation in C 
statistic due to heterogeneity between practices) was 
90.1%. The approximate 95% prediction interval for 
the true C statistic in women in a new practice was 
0.72 to 0.94. Supplementary figure 2c shows the 
corresponding results for model B in women (summary 
C statistic=0.891, I2=77.5%, 95% prediction interval 
0.83 to 0.96).
Calibration
In women, the mean 10 year predicted risk was 
3.62%  for model A and 3.42% for model B. The 
observed 10 year risk was 4.21% (95% confidence 
interval 4.16% to 4.26%). In men, the mean 10 year 
predicted risk was 4.97% for model A and 4.71% for 
model B. The observed 10 year risk was 5.56% (5.48% 
to 5.61%).
Figure 1 shows the mean predicted risks and 
observed risks at 10 years by 10th of predicted risk, 
applying models A, B, and C to all men and women in 
the validation cohort. Supplementary table 7 shows 
values of the calibration slope overall and by subgroup 
for models A and B. For example, the calibration slope 
for model A was 0.997 (0.986 to 1.008) in women 
and 0.986 (0.976 to 0.996) in men. For model B, the 
corresponding values were 0.993 (0.978 to 1.007) 
and 0.985 (0.975 to 0.996). The close correspondence 
between the mean predicted risks and the observed 
risks within each model 10th for each model indicates 
Table 3 | Adjusted hazard ratios (95% confidence interval) for type 2 diabetes in women in the derivation cohort 
for models A, B, and C
Variables
Adjusted hazard ratio (95% CI)
Model A Model B Model C
Townsend score (5 unit increase) 1.21 (1.19 to 1.22) 1.20 (1.18 to 1.21) 1.20 (1.18 to 1.21)
Ethnic group:
 White or not recorded 1.00 1.00 1.00
 Indian 2.91 (2.80 to 3.03) 2.69 (2.57 to 2.81) 1.82 (1.74 to 1.91)
 Pakistani 3.83 (3.66 to 4.01) 3.49 (3.29 to 3.71) 2.19 (2.05 to 2.33)
 Bangladeshi 6.07 (5.77 to 6.38) 4.45 (4.20 to 4.73) 3.30 (3.10 to 3.52)
 Other Asian 3.09 (2.92 to 3.26) 2.63 (2.48 to 2.79) 2.04 (1.92 to 2.17)
 Caribbean 1.52 (1.45 to 1.60) 1.62 (1.54 to 1.71) 1.13 (1.07 to 1.18)
 Black African 1.33 (1.26 to 1.40) 1.61 (1.53 to 1.70) 1.01 (0.96 to 1.07)
 Chinese 2.41 (2.15 to 2.72) 2.12 (1.88 to 2.39) 1.77 (1.53 to 2.05)
 Other 1.44 (1.37 to 1.52) 1.50 (1.42 to 1.58) 1.19 (1.12 to 1.25)
Smoking status:
 Non-smoker 1.00 1.00 1.00
 Former smoker 1.07 (1.05 to 1.09) 1.04 (1.01 to 1.06) 1.07 (1.05 to 1.09)
 Light smoker 1.33 (1.30 to 1.36) 1.25 (1.22 to 1.29) 1.16 (1.13 to 1.19)
 Moderate smoker 1.43 (1.38 to 1.48) 1.36 (1.32 to 1.41) 1.16 (1.12 to 1.21)
 Heavy smoker 1.71 (1.65 to 1.77) 1.55 (1.48 to 1.62) 1.36 (1.29 to 1.43)
Medical characteristics*:
 Family history of diabetes† 1.70 (1.67 to 1.74) 1.57 (1.53 to 1.61) 1.56 (1.52 to 1.59)
 Treated hypertension 1.55 (1.53 to 1.58) 1.33 (1.30 to 1.35) 1.50 (1.47 to 1.53)
 Cardiovascular disease 1.19 (1.16 to 1.23) 1.22 (1.18 to 1.26) 1.18 (1.14 to 1.22)
 Schizophrenia or bipolar affective disorder 1.30 (1.21 to 1.39) 1.18 (1.08 to 1.28) 1.37 (1.27 to 1.49)
 Learning disability† 1.32 (1.19 to 1.46) 1.57 (1.41 to 1.76) 1.34 (1.20 to 1.48)
 Gestational diabetes 4.59 (4.32 to 4.88) 2.91 (2.71 to 3.13) 3.08 (2.87 to 3.31)
 Polycystic ovary syndrome 1.41 (1.33 to 1.49) 1.43 (1.35 to 1.51) 1.40 (1.31 to 1.50)
Current drugs*:
 Statins† 1.93 (1.84 to 2.03) 1.79 (1.70 to 1.88) 1.58 (1.49 to 1.68)
 Atypical antipsychotics† 1.74 (1.60 to 1.89) 1.61 (1.46 to 1.76) 1.73 (1.56 to 1.92)
 Corticosteroids 1.31 (1.28 to 1.34) 1.46 (1.42 to 1.50) 1.18 (1.15 to 1.21)
For fractional polynomial terms and age interactions see figures as well as footnotes.
*Compared with patients without this characteristic.
†Interaction with age; hazard ratio evaluated at mean age.
Model A also includes fractional polynomial terms for age (age0.5, age3) and body mass index (BMI, BMI3) with interaction terms between age and atypical 
antipsychotics, statins, learning disability, body mass index, and family history of diabetes.
Model B same as model A plus fractional polynomial terms for fasting blood glucose (fasting glucose−1, fasting glucose−1 log (fasting glucose)) and 
interaction terms between age and fasting glucose.
Model C same as model A plus fractional polynomial terms for HBA1c (HBA1c0.5, HBA1c) and interaction terms between age and HBA1c.
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that the equations were well calibrated overall and by 
age group. Calibration within subgroups was variable, 
although it tended to be better for model B than for 
model A (see supplementary table 7).
Clinical use of QDiabetes
Figure 2 compares four strategies for identifying high 
risk patients based on current recommendations from 
the NHS Health Checks best practice guide (strategies 
1 and 2) and risk assessment using models B and C 
in combination with model A (strategies 3 and 4). It 
shows that in the validation cohort for the patients 
identified as high risk using model A then strategy 3 
(based on model B) was the most sensitive when equal 
sized groups are compared since it identified 28 953 
(67.3%) of the 43 010 patients with a diagnosis of 
type 2 diabetes during 10 years follow-up who were 
classified as high risk at step 1 (and 49.8% of all 
58 130 patients with a diagnosis of type 2 diabetes 
during 10 years follow-up in the whole validation 
cohort). Strategy 1 (based on a fasting blood glucose 
concentration of 5.5-6.9 mmol/L) identified 27 459 
(63.8% of 43 010 and 47.2% of 58 130) and strategy 4 
(based on model C) identified 27 061 (62.9% of 43 010 
Table 4 | Adjusted hazard ratios (95% confidence interval) for type 2 diabetes in men in the derivation cohort for 
models A, B, and C
Variables
Adjusted hazard ratio (95% CI)
Model A Model B Model C
Townsend score (5 unit increase) 1.14 (1.13 to 1.15) 1.14 (1.12 to 1.15) 1.13 (1.12 to 1.15)
Ethnic group:
 White or not recorded 1.00 1.00 1.00
 Indian 3.00 (2.90 to 3.11) 2.74 (2.64 to 2.84) 1.97 (1.89 to 2.04)
 Pakistani 3.63 (3.48 to 3.79) 3.80 (3.64 to 3.98) 2.30 (2.20 to 2.40)
 Bangladeshi 5.33 (5.09 to 5.59) 4.40 (4.14 to 4.68) 2.99 (2.82 to 3.18)
 Other Asian 3.13 (2.98 to 3.28) 2.82 (2.67 to 2.99) 2.16 (2.04 to 2.28)
 Caribbean 1.60 (1.52 to 1.68) 1.68 (1.59 to 1.78) 1.23 (1.15 to 1.32)
 Black African 2.01 (1.92 to 2.11) 2.36 (2.23 to 2.49) 1.46 (1.39 to 1.54)
 Chinese 1.99 (1.78 to 2.23) 1.90 (1.67 to 2.16) 1.41 (1.22 to 1.62)
 Other 1.52 (1.45 to 1.59) 1.62 (1.55 to 1.70) 1.25 (1.18 to 1.31)
Smoking status:
 Non-smoker 1.00 1.00 1.00
 Former smoker 1.18 (1.16 to 1.20) 1.12 (1.10 to 1.14) 1.12 (1.10 to 1.14)
 Light smoker 1.38 (1.35 to 1.40) 1.36 (1.34 to 1.39) 1.16 (1.13 to 1.18)
 Moderate smoker 1.38 (1.34 to 1.42) 1.39 (1.35 to 1.44) 1.11 (1.07 to 1.16)
 Heavy smoker 1.57 (1.52 to 1.62) 1.53 (1.48 to 1.58) 1.22 (1.18 to 1.26)
Medical characteristics*:
 Family history of diabetes† 1.91 (1.88 to 1.95) 1.78 (1.74 to 1.81) 1.76 (1.72 to 1.80)
 Treated hypertension 1.40 (1.37 to 1.42) 1.28 (1.26 to 1.30) 1.39 (1.36 to 1.43)
 Cardiovascular disease 1.22 (1.20 to 1.25) 1.24 (1.21 to 1.27) 1.16 (1.13 to 1.19)
 Schizophrenia or bipolar affective disorder 1.26 (1.18 to 1.34) 1.24 (1.16 to 1.34) 1.33 (1.24 to 1.43)
 Learning disability† 1.26 (1.16 to 1.38) 1.49 (1.37 to 1.63) 1.30 (1.17 to 1.43)
Current drugs‡:
 Statins† 1.79 (1.74 to 1.86) 1.67 (1.61 to 1.74) 1.53 (1.48 to 1.58)
 Atypical antipsychotics† 1.52 (1.40 to 1.65) 1.56 (1.43 to 1.70) 1.58 (1.44 to 1.72)
 Corticosteroids 1.25 (1.21 to 1.28) 1.41 (1.36 to 1.45) 1.15 (1.11 to 1.18)
For fractional polynomial terms and age interactions see figures as well as footnotes.
*Compared with patients without this characteristic.
†Interaction with age; hazard ratio evaluated at mean age.
Model A also includes fractional polynomial terms for age (ln(age), age3) and body mass index (BMI,2 BMI3) and interactions between age and atypical 
antipsychotics, statins, learning disability, body mass index, family history of diabetes.
Model B is same as model A plus fractional polynomial terms for fasting blood glucose (fasting glucose−0.5, fasting glucose−0.5 log (fasting glucose)) and 
interactions between age and fasting glucose.
Model C is same as model A plus fractional polynomial terms for HBA1c (HBA1c0.5, HBA1c) and interactions between age and HBA1c.
Table 5 | Performance of models A, B, and C compared with current QDiabetes-2017 model in validation cohort in men and women
Statistics Current QDiabetes-2017 model Model A: QDiabetes-2018
Model B: QDiabetes-2018  
(including FBG)
Model C: QDiabetes-2018  
(including HBA1c)
Women:
 D statistic* 2.02 (2.00 to 2.04) 2.07 (2.05 to 2.09) 2.69 (2.65 to 2.73) 2.52 (2.47 to 2.57)
 Harrell’s C* 0.831 (0.828 to 0.833) 0.834 (0.832 to 0.837) 0.889 (0.887 to 0.891) 0.878 (0.875 to 0.881)
 R2 (%)† 49.3 (48.8 to 49.8) 50.5 (50.0 to 51.0) 63.3 (62.7 to 64.0) 60.3 (59.4 to 61.2)
Men:
 D statistic* 1.89 (1.88 to 1.91) 1.91 (1.89 to 1.93) 2.42 (2.40 to 2.45) 2.28 (2.20 to 2.36)
 Harrell’s C* 0.813 (0.810 to 0.815) 0.814 (0.812 to 0.816) 0.866 (0.863 to 0.868) 0.855 (0.849 to 0.861)
 R2 (%)† 46.1 (45.7 to 46.6) 46.6 (46.1 to 47.1) 58.4 (57.9 to 58.8) 55.5 (53.7 to 57.2)
FBG=fasting blood glucose; HBA1c=glycated haemoglobin.
*Measure of discrimination—higher values indicate better discrimination.
†Measures explained variation in time to diagnosis of diabetes —higher values indicate more explained variation.
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Fig 1 | Predicted and observed 10 year risk of diabetes using models A, B, and C
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and 46.6% of 58 130) patients with a diagnosis of type 
2 diabetes during 10 years follow-up. Strategy 2 (based 
on HBA1c values of 42-47 mmol/mol) identified a 
lower proportion of high risk patients (19.1%) and the 
least proportion of patients with a diagnosis of type 2 
diabetes during 10 years follow-up, with only 20 037 
(46.6% of 43 010 and 34.5% of 58 130) identified.
Supplementary table 8 shows the total population, 
number of cases of type 2 diabetes identified during 
follow-up, and the sensitivity, specificity, and observed 
risk at different thresholds of risk for model A. For 
example, using a 10 year risk threshold of 11.1% 
would identify the top 10% of patients with the highest 
risk of diabetes using model A. At this threshold, 
the sensitivity was 45.9%, specificity 90.8%, and 
observed risk 19.3% (95% confidence interval 19.1% 
to 19.5%). Using a risk threshold of 6.6% (the top 
20%) the corresponding values would be 68.1%, 
81.1%, and 14.3%. The thresholds for models B and 
C will vary according to the strategy chosen for the 
initial identification of patients using model A so are 
not presented here.
Figures 3 and 4 are screenshots of the updated web 
calculator with several clinical examples to show how 
QDiabetes-2018 could be used within a consultation. 
Example 1 (figure 3) shows that a white woman aged 
40 years with a body mass index of 30 kg/m2 and a 
family history of diabetes has a 10 year estimated 
risk of type 2 diabetes of 3.6%. If she has polycystic 
ovary syndrome, her risk is 5.0%. If she also has had 
gestational diabetes, her risk is 21.1%. If she also has 
schizophrenia, her risk is 26.5%. If she has a fasting 
glucose value of 5.5 mmol/L, her 10 year risk is 13.7%. 
If her fasting glucose was 6.2 mmol/L, her risk would 
be 67.7%. Example 2 (figure 4) is for a Pakistani man 
aged 35 who has a body mass index of 30 kg/m2. He 
also has schizophrenia and is prescribed atypical 
antipsychotics. His 10 year estimated risk of type 2 
diabetes is 15.6%. If he is prescribed a statin his 10 
year risk is 35.5%. If he has a HBA1c value of 35 mmol/
mol, his 10 year risk is 16.8%.
Decision curve analysis
Figure 5 displays the net benefit curves for men and 
women. These show that the prediction equations 
for models A, B, and C had higher net benefit than 
strategies based on considering either no patients or all 
patients for intervention across a range of thresholds, 
and these are useful up to an absolute risk threshold 
of approximately 40%. Model B had slightly improved 
net benefit compared with model C and both were 
better than model A.
discussion
We have developed and validated updated equations 
to predict the 10 year risk of type 2 diabetes 
(QDiabetes-2017) in men and women aged 25 to 84 
years. The equations incorporate established predictor 
variables as well as new risk factors associated with an 
increased risk of type 2 diabetes. Three models were 
produced: model A includes existing risk factors (age, 
ethnicity, deprivation, body mass index, smoking, 
family history of diabetes in a first degree relative, 
cardiovascular disease, treated hypertension, and 
Adults aged 25-84 in validation cohort (n=2 629 940)
Patients with QDiabetes 10 year risk ≥5.6% (n=627 757, 23.9% of 2 629 940)
Over 10 years, 43 010 patients in this group had a diagnosis of type 2 diabetes, which is 74.0%
of total number of all 58 130 new cases of type 2 diabetes diagnosed over 10 years (n=58 130)
Strategy 4
Model C (HBA1c)
(n=175 771 people,
28.0% of 627 757)
Strategy 3
Model B (FBG)
(n=175 771 people,
28.0% of 627 757)
Strategy 2
HBA1c 42-47 mmol/mol
(n=119 799 people,
19.1% of 627 757)
Strategy 1
FBG 5.5-6.9 mmol/L
(n=177 186 people,
28.2% of 627 757)
27 061 people with
type 2 diabetes identied
(62.9% of 43 010
type 2 diabetes cases)
28 953 people with
type 2 diabetes identied
(67.3% of 43 010
type 2 diabetes cases)
20 037 people with
type 2 diabetes identied
(46.6% of 43 010
type 2 diabetes cases)
27 459 people with
type 2 diabetes identied
(63.8% of 43 010
type 2 diabetes cases)
Step 1: All people assessed using QDiabetes model A according to NHS Health Checks best practice guideline, where people are
  classied as high risk if they have a 10 year risk score of ≥5.6%
Step 2: For people with a QDiabetes 10 year risk score of ≥5.6% compare four strategies:
Strategy 1 — 2017 NHS Health Checks guidance where high risk patients are banded according to their fasting blood glucose (FBG)
                          readings with those who have a value of 5.5-6.9 mmol/L identied as needing intervention
Strategy 2 — 2017 NHS Health Checks guidance where high risk patients are banded according to their glycated haemoglobin
                         (HBA1c) readings with those who have a value of 42-47 mmol/mol identied as needing intervention. This gives the
                          lowest yield, with only 20 037 cases identied
Strategy 3 — new strategy based on QDiabetes model B incorporating FBG as a continuous variable. The top 28% with the highest
                         risk scores (10 year risk ≥13.2%) are identied to give similar numbers of patients to strategy 1. This gives the highest
                         yield, with 28 953 cases of type 2 diabetes identied
Strategy 4 — new strategy based on QDiabetes model C incorporating HBA1c as a continuous variable. The top 28% with the highest
                         risk scores (10 year risk of ≥14.3%) are identied to give similar numbers of patients to strategies 1 and 3
Fig 2 | Comparison of four strategies for identifying patients at high risk of developing diabetes. FBG=fasting blood 
glucose
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About you Your results
Your risk of having type 2 diabetes within the next 10 years is:
In other words, in a crowd of 100 people with the same risk factors as you,
27 are likely to have type 2 diabetes within the next 10 years.
Your score has been calculated using estimated data, as some information
has been le blank
Your body mass index was calculated as 30.12 kg/m2
UK postcode: leave blank if unknown
Women only
Age (25-84):
Sex: Male
Ethnicity:
40
26.5%
Risk of type 2 diabetes
Clinical information
Smoking status:
Do immediate family (mother, father, brothers,
or sisters have diabetes?
Have you had a heart attack, angina, stroke, or TIA?
non-smoker
Postcode:
Body mass index
Height (cm):
White or not stated
Female
Do you have high blood pressure requiring
treatment?
Learning diculties?
Do you have polycystic ovary syndrome?
Are you taking regular steroid tablets?
Are you taking statins?
Using atypical antipsychotic medication?
Schizophrenia or bipolar aective disorder?
✓
Do you have gestational diabetes (ie,
diabetes that arose during pregnancy?
Leave blank if unknown
Fasting blood glucose (mmol/L):
HBA1c (mmol/mol):
✓
✓
✓
165
Weight (kg): 82
About you Your results
Your risk of having type 2 diabetes within the next 10 years is:
In other words, in a crowd of 100 people with the same risk factors as you,
68 are likely to have type 2 diabetes within the next 10 years.
Your score has been calculated using estimated data, as some information
has been le blank
Your body mass index was calculated as 30.12 kg/m2
UK postcode: leave blank if unknown
Women only
Age (25-84):
Sex: Male
Ethnicity:
40
67.7%
Risk of type 2 diabetes
Clinical information
Smoking status:
Do immediate family (mother, father, brothers,
or sisters have diabetes?
Have you had a heart attack, angina, stroke, or TIA?
non-smoker
Postcode:
Body mass index
Height (cm):
White or not stated
Female
Do you have high blood pressure requiring
treatment?
Learning diculties?
Do you have polycystic ovary syndrome?
Are you taking regular steroid tablets?
Are you taking statins?
Using atypical antipsychotic medication?
Schizophrenia or bipolar aective disorder?
✓
Do you have gestational diabetes (ie,
diabetes that arose during pregnancy?
Leave blank if unknown
Fasting blood glucose (mmol/L):
HBA1c (mmol/mol):
✓
✓
165
6.2
Weight (kg): 82
✓
Fig 3 | Clinical example 1: Using QDiabetes to calculate absolute risk of diabetes in a female patient. TIA=transient ischaemic attack
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About you Your results
Your risk of having type 2 diabetes within the next 10 years is:
In other words, in a crowd of 100 people with the same risk factors as you,
36 are likely to have type 2 diabetes within the next 10 years.
Your score has been calculated using estimated data, as some information
has been le blank
Your body mass index was calculated as 30.12 kg/m2
UK postcode: leave blank if unknown
Age (25-84):
Sex: Male
Ethnicity:
35
35.5%
Risk of type 2 diabetes
Postcode:
Pakistani
Female
About you Your results
Your risk of having type 2 diabetes within the next 10 years is:
In other words, in a crowd of 100 people with the same risk factors as you,
17 are likely to have type 2 diabetes within the next 10 years.
Your score has been calculated using estimated data, as some information
has been le blank
Your body mass index was calculated as 30.12 kg/m2
UK postcode: leave blank if unknown
Age (25-84):
Sex: Male
Ethnicity:
35
16.8%
Postcode:
Pakistani
Female
Women only
Clinical information
Smoking status:
Do immediate family (mother, father, brothers,
or sisters have diabetes?
Have you had a heart attack, angina, stroke, or TIA?
non-smoker
Body mass index
Height (cm):
Do you have high blood pressure requiring
treatment?
Learning diculties?
Do you have polycystic ovary syndrome?
Are you taking regular steroid tablets?
Are you taking statins?
Using atypical antipsychotic medication?
Schizophrenia or bipolar aective disorder?
Do you have gestational diabetes (ie,
diabetes that arose during pregnancy?
Leave blank if unknown
Fasting blood glucose (mmol/L):
HBA1c (mmol/mol):
✓
✓
✓
165
Weight (kg): 82
Women only
Clinical information
Smoking status:
Do immediate family (mother, father, brothers,
or sisters have diabetes?
Have you had a heart attack, angina, stroke, or TIA?
non-smoker
Body mass index
Height (cm):
Do you have high blood pressure requiring
treatment?
Learning diculties?
Do you have polycystic ovary syndrome?
Are you taking regular steroid tablets?
Are you taking statins?
Using atypical antipsychotic medication?
Schizophrenia or bipolar aective disorder?
✓
Do you have gestational diabetes (ie,
diabetes that arose during pregnancy?
Leave blank if unknown
Fasting blood glucose (mmol/L):
HBA1c (mmol/mol):
✓
165
35
Weight (kg): 82
✓
✓
Fig 4 | Clinical example 2: Using QDiabetes to calculate absolute risk of diabetes in a male patient. TIA=transient ischaemic attack
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regular use of corticosteroids) and new risk factors 
(atypical antipsychotics, statins, schizophrenia 
or bipolar affective disorder, learning disability, 
gestational diabetes, and polycystic ovary syndrome). 
The inclusion of these new risk factors will help 
ensure more accurate estimation of the level of risk 
in the affected population to improve information for 
individual patients and for surveillance strategies.
Although the new models are more complex than 
the existing models, this is unlikely to affect the 
uptake of the new models as they are all designed to 
be calculated automatically based on information 
recorded in the electronic patient record. Figures 
3 and 4 included case studies where the impact of 
additional risk factors for an example patient would 
lead to different management. For individuals, the 
presence of these new risk factors could substantially 
increase their absolute risks of diabetes. These 
changes in absolute risk could push individuals over 
a risk threshold, which may then result in different 
clinical management. However, the actual numbers 
of people in these groups are comparatively small, so 
the discrimination statistics are too crude to be able to 
detect these effects in individuals.
In addition, we have developed two further models, 
which include blood test results in addition to the risk 
factors from model A. Model B includes fasting blood 
glucose and model C includes glycated haemoglobin 
(HBA1c) as continuous values. This approach improves 
on current approaches using fixed thresholds for 
fasting blood glucose or HBA1c,12 51 as it takes other 
risk factors into account and allows a more precise 
estimation of risk to be communicated to patients. 
The new models can be used to support the two step 
approach to the identification of patients at high risk 
of diabetes, as recommended by NICE guidance13 and 
the NHS Health Checks.12 Model A could be used to 
identify those at high risk of diabetes who require a test 
for fasting blood glucose or HBA1c. After identifying 
those patients who meet the criteria for a diagnosis 
of diabetes, model B could be used to refine the risk 
estimation in the remaining patients once the result 
of the fasting blood glucose test is known, since this 
information provides a more accurate assessment of 
risk. Similarly, model C could be used when the HBA1c 
test result is known. Model B had better discrimination 
and explained more of the variation in time to diagnosis 
of diabetes than model C. Model B also had the highest 
sensitivity for identifying cases of diabetes (fig 2), 
identifying more than two thirds of cases in those 
determined as being high risk at step 1 compared with 
the current NHS strategy based on bands of HBA1c that 
had the lowest sensitivity. Model B also had the highest 
net benefit, as shown by the decision analysis curve in 
figure 5, although it was only a small improvement on 
model C. The strategy based on model B identified a 
high risk group of 6.7% of the validation cohort, which 
included nearly half (49.8%) of all patients with a 
diagnosis of type 2 diabetes over 10 years. Overall, 
use of model B in strategy 3 and model C in strategy 
4 (fig 2) gives more accurate predictions of the future 
diabetes risk among those tested compared with either 
strategy 1 or 2 based on blood tests alone.
Comparisons with the literature
The hazard ratios for the new risk variables included 
in our final models are similar in both magnitude and 
direction to those reported in other studies.
Antipsychotics, mental health problems, and 
learning disabilities—Recent published NICE guidance 
on identification of people at risk of type 2 diabetes 
highlights the increased risk associated with learning 
disabilities and mental health problems.14 Learning 
disabilities affected approximately 1% of our derivation 
cohort and were associated with a 32% increased risk 
of diabetes in women and 26% increased risk in men at 
the mean age (model A). This is consistent with other 
studies15 and is likely to be related to adverse lifestyle 
factors, including lack of exercise.52 Schizophrenia or 
bipolar affective disorder also affected approximately 
1% of patients and was associated with a 30% increased 
risk of diabetes in women and a 26% increased risk 
in men. Atypical antipsychotics were prescribed for 
approximately 1% of patients. They were associated 
with a 74% increased risk of diabetes in women and 
52% increased risk in men. This is independent of the 
risk associated with schizophrenia or bipolar affective 
disorder, and hence if patients have both factors there 
will be a compound effect on risk of diabetes. The 
magnitude of this increased risk was consistent with 
other studies.16 Although the prevalence of each of 
these conditions is approximately 1%, the magnitude 
of the effect is substantial and likely to represent an 
Threshold probability
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0 0.1 0.2 0.3 0.4 0.5
-0.04
0
0.02
0.04
-0.02
Net benet: treat all
Model A
Model B
Model C
Net benet: treat none
Men
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e
t
-0.05
0
0.05
Fig 5 | Net benefit curves for men and women
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important clinical problem for patients. Clinicians will 
now be able to use QDiabetes-2018 to provide better 
information to these patients about both the potential 
effects of atypical antipsychotics and the interventions 
to reduce the risk of diabetes.
Statins—The increased risk of type 2 diabetes 
associated with statin use is established. A meta-
analysis of 13 statin trials reported a 9% (95% 
confidence interval 2% to 17%) increased risk.20 
The risk associated with statin use was higher in our 
study than in the trials, which may reflect targeting of 
statins towards those who are already at higher risk of 
diabetes. Also, the participants in the meta-analysis 
trials were substantially older (mean age 65 years) 
than our study participants (mean age 45 years). When 
similar age groups are compared, the magnitude of the 
increased risk associated with statins in our study is 
broadly comparable with that reported in the meta-
analysis of clinical trials,20 reflecting the interaction 
between age and statin use. While the magnitude of 
the diabetes risk associated with statins was of similar 
magnitude to the increased risk found for atypical 
antipsychotic drugs, the public health implications 
may be greater because statins are one of the most 
commonly prescribed medicines internationally 
and are targeted at those who already have adverse 
cardiovascular risk profiles. However, the increased 
diabetes risk with statins needs to be balanced against 
the potential reduction in coronary events,20 making 
the provision of accurate information on risks and 
benefits of statins even more important.
Gestational  diabetes  and  polycystic  ovary 
syndrome—We studied two risk factors (gestational 
diabetes and polycystic ovary syndrome) that only 
occur in women. Polycystic ovary syndrome is known 
to be associated with an increased prevalence of 
diabetes.53 It has recently been identified as a risk 
factor for type 2 diabetes.54 55 We found that polycystic 
ovary syndrome affected 2% of women at baseline, 
and it was associated with a 41% increased risk in 
model A. We also found that gestational diabetes was 
associated with a 4.6-fold increased risk of diabetes, 
confirming that it is one of the strongest risk factors 
for the subsequent development of type 2 diabetes.56 
57 Although recent NICE guidance on diabetes in 
pregnancy in 2008 and 201558 recommends annual 
blood glucose testing postnatally for women with a 
diagnosis of gestational diabetes, only 20% of such 
women receive regular screening in primary care.59 
The inclusion of both polycystic ovary syndrome and 
gestational diabetes in QDiabetes-2018 will ensure the 
presence of an automated integrated tool available in 
general practice computer systems to alert clinicians to 
these patients’ increased risk of diabetes and facilitate 
proactive follow-up in primary care.
Comparison with original version of 
QDiabetes-2009—Our first QDiabetes model, published 
in 2009, was based on a cohort followed up between 
1993 and 2008. Since then improvements have been 
made to the QResearch database used to derive the 
equation, which may have resulted in changes to 
the model. For example, the number of practices 
contributing to the database has almost tripled, from 
531 in 2009 to 1465 in this study. The size of the 
derivation cohort has increased threefold, with 178 314 
diagnoses of type 2 diabetes arising from 42.7 million 
person years of observation compared with 78 081 
diagnoses of type 2 diabetes arising from 16.4 million 
person years in 2009.1 The recorded prevalence of 
family history of diabetes has increased by 50%, rising 
from 9.9% to 14.9%. The baseline prevalence of treated 
hypertension and corticosteroids have each doubled. 
The recording of self assigned ethnicity has increased 
threefold, from 24% to 72.5% in the current study. As 
a result, we have many more events within the various 
subgroups. This is reflected in the more precise hazard 
ratios with tighter confidence intervals and improved 
performance statistics. Interestingly, the hazard ratios 
by ethnic group varied between the different models, 
with models B and C tending to have lower values 
for non-white ethnic groups compared with model A. 
The discrimination statistics were, however, broadly 
similar. Overall, the new models are well calibrated 
when applied to a separate validation cohort and 
have high levels of discrimination. Although model 
A had similar performance to the current QDiabetes 
model, the other two models showed considerable 
improvement, with the best overall performance for 
model B.
Further methodological considerations
The methods to derive and validate these models 
are broadly the same as for a range of other clinical 
risk prediction tools derived from the QResearch 
database.1 29 60-63 The strengths and limitations of the 
approach have already been discussed in detail.1 6 31 
62-65 In summary, key strengths include size, duration 
of follow-up, representativeness, and lack of selection, 
recall, and respondent bias. UK general practices 
have good levels of accuracy and completeness in 
recording clinical diagnoses and prescribed drugs.66 
Our study included approximately 20% of all general 
practices in England, and the characteristics of the 
population registered with QResearch are similar to the 
population registered with other large general practice 
databases using other clinical computer systems.5 It is 
therefore likely to be representative of the population 
overall, especially since approximately 98% of the UK 
population is registered with a general practice. Of all 
the patients with type 1 or type 2 diabetes excluded 
at baseline, 9.1% were classified as having type 1 
diabetes, which is consistent with other studies using 
different approaches.67 68 We think our study has good 
face validity as it has been conducted in the setting 
where most patients in the UK are assessed, treated, 
and followed up.
Limitations of this study
Limitations of our study include the lack of formal 
adjudication of diagnoses, information bias, and 
potential for bias because of missing data. Fractional 
polynomial terms were identified using complete 
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rather than imputed data. This may have resulted in 
some bias or less power to detect non-linear trends.69 
Only 16% of patients had complete data for blood 
glucose measurements, smoking, and body mass 
index. However, the characteristics of patients and 
the magnitude of the hazard ratios on the complete 
case analysis were broadly similar for both magnitude 
and direction to the analysis based on imputed data 
(results shown in supplementary tables 3 and 4), 
which is reassuring. We used five imputations, which 
may be fewer than recommended because of practical 
considerations given the huge size of the dataset. 
However, given the high degree of missing data for 
models B and C, additional external validation of these 
models in datasets with more completely collected 
data would be valuable before the models are used in 
clinical practice.
Some under-ascertainment of diagnoses of type 2 
diabetes might be present leading to misclassification 
bias for the outcome. This is because not all patients 
will have consulted their general practitioner during 
the study period and been screened for diabetes. 
Similarly, there may be under-ascertainment of some 
of the predictor variables such as polycystic ovary 
syndrome and gestational diabetes, as the baseline 
prevalence is lower than in other studies.67 This may be 
because gestational diabetes had not been diagnosed 
or that the diagnosis had not been recorded on the 
general practice electronic health record. Another 
limitation is that we have not been able to use oral 
glucose tolerance testing as a predictor variable as 
the results of these tests are not stored routinely in the 
general practice record. We have not taken account of 
competing risks in this analysis because the results 
can be counterintuitive70 and difficult to use in clinical 
practice.71 However, not accounting for the competing 
risk of death in elderly patients is likely to result in risk 
estimates that are too high in this age group.
We excluded patients without a valid deprivation 
score as this group may represent a more transient 
population where follow-up could be unreliable or 
unrepresentative. Their deprivation scores are unlikely 
to be missing at random so we did not think it would be 
appropriate to impute them.
Some overfitting might have occurred, but this is 
unlikely given  the  large number of events. Generally, 
to avoid overfitting it is recommended that there are 
at least 10 events per predictor variable, including the 
interaction terms.72 Our most complex model (model C 
in women) had 45 predictor variables. Our derivation 
sample had 178 314 events, giving 3962 events per 
predictor variable, which is nearly 400 times the 
minimum recommended level.
The present validation has been done on a randomly 
selected separate set of practices and individuals to 
those that were used to develop the score, although 
the practices all use the same general practice clinical 
computer system (EMIS, the computer system used 
by 58% of general practices in England). Some 
researchers argue that a split sample validation is not 
necessary when the sample is large enough,73 as in 
our study. Others argue that a split sample validation 
is still valuable. However, since randomly splitting a 
huge dataset is likely to result in similar populations, it 
is preferable to split by time or geographical location to 
obtain a a non-random selection of practices covering 
a broader range of settings.40 An independent external 
validation study would be a more stringent test and 
should be done, but when such studies have examined 
QDiabetes67and other risk equations,65 74 75 they have 
shown comparable performance to the validation in 
the QResearch database.67 We have published the 
source code to enable accurate implementation of 
QDiabetes-2018 on the QDiabetes website (www.
qdiabetes.org) alongside earlier versions of the score 
from previous updates. The rationale for this is to 
ensure that those interested in reviewing or using the 
open source will then be able to find the latest available 
version as the score continues to be updated.
Conclusions
We have developed updated risk equations 
(QDiabetes-2018) to quantify absolute risks of type 2 
diabetes in people aged 25-84 years, which include 
established risk factors and new risk factors: atypical 
antipsychotics, statins, schizophrenia or bipolar 
affective disorder, learning disability, gestational 
diabetes, and polycystic ovary syndrome. The updated 
risk equations provide valid measures of absolute risk 
in the general population of patients, as shown by 
the performance in a separate validation cohort. The 
addition of fasting blood glucose to the updated model 
(model B) had the best discrimination and sensitivity 
and potentially improves on currently available risk 
assessment approaches to identify those at risk of 
diabetes.
A simple web calculator (http://qdiabetes.org/2018) can be used to 
implement the QDiabetes-2018 algorithm. The website also has the 
open source software for download.
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